Skip to main content

ABBV-022

Targeted delivery of IL-22 to epithelial surface of damaged gut mucosa will promote survival of intestinal stem cells, improve goblet cell function and epithelial barrier thereby reducing inflammation and clinical signs of disease.

Type of Molecule

Biologic

Target

Il-22

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Ulcerative Colitis n/a
Phase 1